$PPHM Recent Headlines Peregrine plunges on te
Post# of 74551
Posted On: 06/30/2014 9:52:39 AM
$PPHM Recent Headlines
Peregrine plunges on test data 4:17 p.m. June 27, 2013 - Russ Britt
Small-cap makes a splash with FDA nod for cancer drug 3:16 p.m. May 20, 2013 - Russ Britt
Peregrine drug shows promise in pancreatic cancer 1:17 p.m. Feb. 13, 2013 - MarketWatch.com
In focus: Bullish, but overbought 8:06 p.m. Jan. 9, 2013 - Lawrence G. McMillan
Hedge funds are bullish on these stocks 11:57 a.m. Dec. 5, 2012 - Insider Monkey
Peregrine, FDA agree on brain-cancer drug study 11:56 a.m. Dec. 5, 2012 - MarketWatch.com
Drug trial contractors improve efficiency 10:24 a.m. Nov. 16, 2012 - MarketWatch.com
Monday’s biggest gaining and declining stocks 6:42 p.m. Sept. 25, 2012 - Greg Morcroft
Tuesday’s biggest gaining and declining stocks 5:09 p.m. Sept. 25, 2012 - Greg Morcroft
Peregrine Pharma down 86% after test data review 8:27 a.m. Sept. 24, 2012 - Steve Gelsi
Peregrine Pharma down 86% in premarket 8:18 a.m. Sept. 24, 2012 - Steve Gelsi
Peregrine reviewing Bavituximab results 7:42 a.m. Sept. 24, 2012 - Greg Morcroft
Some previous Bavituximab data not valid
eregrine 7:42 a.m. Sept. 24, 2012 - Greg Morcroft
Monday’s biggest gaining and declining stocks 2:42 p.m. Sept. 10, 2012 - MarketWatch
Regions Financial, Williams-Sonoma hit 52-week highs; Intel, Cisco active 11:11 a.m. Sept. 10, 2012 - blogs.marketwatch.com
Stocks to watch Monday: AIG, Michael Kors, Sears 6:41 a.m. Sept. 10, 2012 - MarketWatch
Peregrine rallies on bavituximab lung-cancer data 1:29 p.m. Sept. 7, 2012 - MarketWatch.com
Monday’s biggest gaining & declining stocks 2:53 p.m. Aug. 27, 2012 - MarketWatch
Peregrine Pharma slides 12% after negative report 2:21 p.m. Aug. 27, 2012 - Val Brickates Kennedy
Monday’s biggest gaining and declining stocks 4:23 p.m. May 21, 2012 - MarketWatch
First Week Of January 2015 Options Trading For Peregrine Pharmaceuticals (PPHM) 11:09 a.m. May 20, 2014 - TheStreet.com
Biotech Stock Mailbag: Sarepta, F-R Rule Stock Predictions, Merrimack 6:00 a.m. May 9, 2014 - TheStreet.com
Peregrine wins law suit 9:24 a.m. May 5, 2014 - Seeking Alpha
Medivation Signs Deal with OncoFusion Therapeutics - Analyst Blog 6:24 p.m. April 24, 2014 - Zacks.com
Interesting PPHM Call Options For June 21st 11:02 a.m. April 23, 2014 - TheStreet.com
Peregrine's Bavituximab has high success rate in animal testing 9:47 a.m. April 7, 2014 - Seeking Alpha
Peregrine Pharmaceuticals (PPHM) Shares March Higher, Can It Continue? - Tale of the Tape 8:39 a.m. March 18, 2014 - Zacks.com
Cel-Sci's Multikine - Potential 21st Century Superdrug 5:41 p.m. March 13, 2014 - Seeking Alpha
Peregrine antibodies boost anti-tumor activity in animal studies 9:47 a.m. March 11, 2014 - Seeking Alpha
Loss Widens at Peregrine, Shares Down - Analyst Blog 9:40 a.m. March 11, 2014 - Zacks.com
Peregrine Pharmaceuticals Management Discusses Q3 2014 Results - Earnings Call Transcript 3:40 p.m. March 7, 2014 - Seeking Alpha
10-Q: PEREGRINE PHARMACEUTICALS INC 2:34 p.m. March 7, 2014 - Edgar Online - (EDG = 10Q, 10K)
Peregrine Pharmaceuticals Inc. Discusses Q3 2014 Results (Webcast) 11:55 a.m. March 7, 2014 - Seeking Alpha
Peregrine Move Looks Sustainable, at Least for Now 7:45 a.m. March 6, 2014 - 247WallSt.com
The Race For A Cure For Cancer, The Final Chapter 4:07 p.m. Feb. 19, 2014 - Seeking Alpha
Could Lilly's Ramucirumab kill off Peregrine's Bavituximab? 9:55 a.m. Feb. 19, 2014 - Seeking Alpha
Dear Healthcare Investors: The Correction, It's Here 6:16 a.m. Feb. 4, 2014 - Seeking Alpha
Peregrine Pharmaceuticals (PPHM) Jumps: Stock Up 7.6% - Tale of the Tape 9:51 a.m. Jan. 22, 2014 - Zacks.com
4 Biotechnology Stocks to Sell Now 6:15 a.m. Jan. 15, 2014 - InvestorPlace.com
Fast Track Status for Peregrine Candidate - Analyst Blog 6:20 p.m. Jan. 7, 2014 - Zacks.com
Technical Scrutiny on Biotech Stocks -- Research on Insmed, Peregrine Pharma, CytRx, and Celldex Therapeutics 6:40 a.m. Today - PR Newswire - PRF
Peregrine Pharmaceuticals Declares Quarterly Dividend on Its Series E Convertible Preferred Stock 4:00 p.m. June 10, 2014 - Marketwire
Pre-Market Review on Biotechnology Equities -- Research on BioMarin Pharma, Keryx Biopharma, Amgen, and Peregrine Pharma 8:30 a.m. May 30, 2014 - PR Newswire - PRF
Biotech Stocks Scanner -- Research on PDL BioPharma, Cytokinetics, Vical, and Peregrine Pharma 12:41 p.m. May 6, 2014 - PR Newswire - PRF
Peregrine Pharmaceuticals Announces Initiation of an Investigator-Sponsored Trial Combining Its Immunotherapy Bavituximab and Ipilimumab (Yervoy(R)) in Advanced Melanoma 7:31 a.m. April 23, 2014 - Marketwire
Healthcare Companies Report Results, Patents, and Stock Movements - Analyst Notes on Puma Biotechnology, Alnylam, INSYS Therapeutics, Peregrine Pharmaceuticals, and VIVUS 12:28 p.m. April 10, 2014 - PR Newswire - PRF
Data Presented at AACR Support Potential of Peregrine's PS-Targeting Immunotherapy Bavituximab to Enhance Anti-Tumor and Immune-Stimulating Effects of Anti-CTLA-4 and Anti-PD-1 Treatments in Models of Melanoma and Colon Cancer 11:01 a.m. April 9, 2014 - Marketwire
Morning Review on Top Gainers -- Research on Peregrine Pharma, Agios Pharma, Idenix Pharma, and Lexicon Pharma 1:15 p.m. April 8, 2014 - PR Newswire - PRF
Data Presented at AACR Support Potential of Combining Peregrine's PS-Targeting Immunotherapy Agent Bavituximab With Irradiation in Lung Cancer 8:04 a.m. April 7, 2014 - Marketwire
Peregrine Pharmaceuticals Announces Three Abstracts Accepted for Presentation at AACR 2014 Annual Meeting 4:01 p.m. April 1, 2014 - Marketwire
Presentation at Annual Society of Surgical Oncology Meeting Updates Progress in Investigator-Sponsored Phase i/ii Trial of Peregrine's Bavituximab in Combination With Sorafenib in Liver Cancer 8:02 a.m. March 14, 2014 - Marketwire
Preclinical Data Presentations at Keystone Symposia Highlight Broad Immunotherapy Potential of Peregrine Pharmaceuticals' PS-Targeting Antibodies 8:02 a.m. March 13, 2014 - Marketwire
Peregrine Pharmaceuticals Declares Quarterly Dividend on Its Series E Convertible Preferred Stock 4:11 p.m. March 11, 2014 - Marketwire
Data Presentations at Keystone Symposium Support Potential of Peregrine Pharmaceuticals' PS-Targeting Antibodies to Overcome Immune Suppression and Enhance Anti-Tumor Activity of Anti-CTLA-4 and PD-1 Antibodies 8:04 a.m. March 11, 2014 - Marketwire
Peregrine Pharmaceuticals Reports Third Quarter Fiscal Year 2014 Financial Results and Recent Developments 9:01 a.m. March 7, 2014 - Marketwire
Pre-Market Review of Top Gainers: Canadian Solar, Qihoo 360 Technology, Peregrine Pharma, Renren, and UTi Worldwide 11:40 a.m. March 5, 2014 - PR Newswire - PRF
Peregrine Pharmaceuticals PS-Targeting Immunotherapy Platform to Be Highlighted in Three Data Presentations at Keystone Symposia Conferences 5:01 p.m. March 4, 2014 - Marketwire
Peregrine Pharmaceuticals to Report Third Quarter Fiscal Year 2014 Financial Results Before Market Open on March 7, 2014 5:01 p.m. Feb. 27, 2014 - Marketwire
Peregrine Pharmaceuticals Announces Partial Exercise of Overallotment Option in Connection With Preferred Stock Offering 1:20 p.m. Feb. 27, 2014 - Marketwire
Hercules Offshore Losses Decrease from $121 million to $27 million 10:17 a.m. Feb. 24, 2014 - ACCESSWIRE
Peregrine plunges on test data 4:17 p.m. June 27, 2013 - Russ Britt
Small-cap makes a splash with FDA nod for cancer drug 3:16 p.m. May 20, 2013 - Russ Britt
Peregrine drug shows promise in pancreatic cancer 1:17 p.m. Feb. 13, 2013 - MarketWatch.com
In focus: Bullish, but overbought 8:06 p.m. Jan. 9, 2013 - Lawrence G. McMillan
Hedge funds are bullish on these stocks 11:57 a.m. Dec. 5, 2012 - Insider Monkey
Peregrine, FDA agree on brain-cancer drug study 11:56 a.m. Dec. 5, 2012 - MarketWatch.com
Drug trial contractors improve efficiency 10:24 a.m. Nov. 16, 2012 - MarketWatch.com
Monday’s biggest gaining and declining stocks 6:42 p.m. Sept. 25, 2012 - Greg Morcroft
Tuesday’s biggest gaining and declining stocks 5:09 p.m. Sept. 25, 2012 - Greg Morcroft
Peregrine Pharma down 86% after test data review 8:27 a.m. Sept. 24, 2012 - Steve Gelsi
Peregrine Pharma down 86% in premarket 8:18 a.m. Sept. 24, 2012 - Steve Gelsi
Peregrine reviewing Bavituximab results 7:42 a.m. Sept. 24, 2012 - Greg Morcroft
Some previous Bavituximab data not valid
eregrine 7:42 a.m. Sept. 24, 2012 - Greg Morcroft Monday’s biggest gaining and declining stocks 2:42 p.m. Sept. 10, 2012 - MarketWatch
Regions Financial, Williams-Sonoma hit 52-week highs; Intel, Cisco active 11:11 a.m. Sept. 10, 2012 - blogs.marketwatch.com
Stocks to watch Monday: AIG, Michael Kors, Sears 6:41 a.m. Sept. 10, 2012 - MarketWatch
Peregrine rallies on bavituximab lung-cancer data 1:29 p.m. Sept. 7, 2012 - MarketWatch.com
Monday’s biggest gaining & declining stocks 2:53 p.m. Aug. 27, 2012 - MarketWatch
Peregrine Pharma slides 12% after negative report 2:21 p.m. Aug. 27, 2012 - Val Brickates Kennedy
Monday’s biggest gaining and declining stocks 4:23 p.m. May 21, 2012 - MarketWatch
First Week Of January 2015 Options Trading For Peregrine Pharmaceuticals (PPHM) 11:09 a.m. May 20, 2014 - TheStreet.com
Biotech Stock Mailbag: Sarepta, F-R Rule Stock Predictions, Merrimack 6:00 a.m. May 9, 2014 - TheStreet.com
Peregrine wins law suit 9:24 a.m. May 5, 2014 - Seeking Alpha
Medivation Signs Deal with OncoFusion Therapeutics - Analyst Blog 6:24 p.m. April 24, 2014 - Zacks.com
Interesting PPHM Call Options For June 21st 11:02 a.m. April 23, 2014 - TheStreet.com
Peregrine's Bavituximab has high success rate in animal testing 9:47 a.m. April 7, 2014 - Seeking Alpha
Peregrine Pharmaceuticals (PPHM) Shares March Higher, Can It Continue? - Tale of the Tape 8:39 a.m. March 18, 2014 - Zacks.com
Cel-Sci's Multikine - Potential 21st Century Superdrug 5:41 p.m. March 13, 2014 - Seeking Alpha
Peregrine antibodies boost anti-tumor activity in animal studies 9:47 a.m. March 11, 2014 - Seeking Alpha
Loss Widens at Peregrine, Shares Down - Analyst Blog 9:40 a.m. March 11, 2014 - Zacks.com
Peregrine Pharmaceuticals Management Discusses Q3 2014 Results - Earnings Call Transcript 3:40 p.m. March 7, 2014 - Seeking Alpha
10-Q: PEREGRINE PHARMACEUTICALS INC 2:34 p.m. March 7, 2014 - Edgar Online - (EDG = 10Q, 10K)
Peregrine Pharmaceuticals Inc. Discusses Q3 2014 Results (Webcast) 11:55 a.m. March 7, 2014 - Seeking Alpha
Peregrine Move Looks Sustainable, at Least for Now 7:45 a.m. March 6, 2014 - 247WallSt.com
The Race For A Cure For Cancer, The Final Chapter 4:07 p.m. Feb. 19, 2014 - Seeking Alpha
Could Lilly's Ramucirumab kill off Peregrine's Bavituximab? 9:55 a.m. Feb. 19, 2014 - Seeking Alpha
Dear Healthcare Investors: The Correction, It's Here 6:16 a.m. Feb. 4, 2014 - Seeking Alpha
Peregrine Pharmaceuticals (PPHM) Jumps: Stock Up 7.6% - Tale of the Tape 9:51 a.m. Jan. 22, 2014 - Zacks.com
4 Biotechnology Stocks to Sell Now 6:15 a.m. Jan. 15, 2014 - InvestorPlace.com
Fast Track Status for Peregrine Candidate - Analyst Blog 6:20 p.m. Jan. 7, 2014 - Zacks.com
Technical Scrutiny on Biotech Stocks -- Research on Insmed, Peregrine Pharma, CytRx, and Celldex Therapeutics 6:40 a.m. Today - PR Newswire - PRF
Peregrine Pharmaceuticals Declares Quarterly Dividend on Its Series E Convertible Preferred Stock 4:00 p.m. June 10, 2014 - Marketwire
Pre-Market Review on Biotechnology Equities -- Research on BioMarin Pharma, Keryx Biopharma, Amgen, and Peregrine Pharma 8:30 a.m. May 30, 2014 - PR Newswire - PRF
Biotech Stocks Scanner -- Research on PDL BioPharma, Cytokinetics, Vical, and Peregrine Pharma 12:41 p.m. May 6, 2014 - PR Newswire - PRF
Peregrine Pharmaceuticals Announces Initiation of an Investigator-Sponsored Trial Combining Its Immunotherapy Bavituximab and Ipilimumab (Yervoy(R)) in Advanced Melanoma 7:31 a.m. April 23, 2014 - Marketwire
Healthcare Companies Report Results, Patents, and Stock Movements - Analyst Notes on Puma Biotechnology, Alnylam, INSYS Therapeutics, Peregrine Pharmaceuticals, and VIVUS 12:28 p.m. April 10, 2014 - PR Newswire - PRF
Data Presented at AACR Support Potential of Peregrine's PS-Targeting Immunotherapy Bavituximab to Enhance Anti-Tumor and Immune-Stimulating Effects of Anti-CTLA-4 and Anti-PD-1 Treatments in Models of Melanoma and Colon Cancer 11:01 a.m. April 9, 2014 - Marketwire
Morning Review on Top Gainers -- Research on Peregrine Pharma, Agios Pharma, Idenix Pharma, and Lexicon Pharma 1:15 p.m. April 8, 2014 - PR Newswire - PRF
Data Presented at AACR Support Potential of Combining Peregrine's PS-Targeting Immunotherapy Agent Bavituximab With Irradiation in Lung Cancer 8:04 a.m. April 7, 2014 - Marketwire
Peregrine Pharmaceuticals Announces Three Abstracts Accepted for Presentation at AACR 2014 Annual Meeting 4:01 p.m. April 1, 2014 - Marketwire
Presentation at Annual Society of Surgical Oncology Meeting Updates Progress in Investigator-Sponsored Phase i/ii Trial of Peregrine's Bavituximab in Combination With Sorafenib in Liver Cancer 8:02 a.m. March 14, 2014 - Marketwire
Preclinical Data Presentations at Keystone Symposia Highlight Broad Immunotherapy Potential of Peregrine Pharmaceuticals' PS-Targeting Antibodies 8:02 a.m. March 13, 2014 - Marketwire
Peregrine Pharmaceuticals Declares Quarterly Dividend on Its Series E Convertible Preferred Stock 4:11 p.m. March 11, 2014 - Marketwire
Data Presentations at Keystone Symposium Support Potential of Peregrine Pharmaceuticals' PS-Targeting Antibodies to Overcome Immune Suppression and Enhance Anti-Tumor Activity of Anti-CTLA-4 and PD-1 Antibodies 8:04 a.m. March 11, 2014 - Marketwire
Peregrine Pharmaceuticals Reports Third Quarter Fiscal Year 2014 Financial Results and Recent Developments 9:01 a.m. March 7, 2014 - Marketwire
Pre-Market Review of Top Gainers: Canadian Solar, Qihoo 360 Technology, Peregrine Pharma, Renren, and UTi Worldwide 11:40 a.m. March 5, 2014 - PR Newswire - PRF
Peregrine Pharmaceuticals PS-Targeting Immunotherapy Platform to Be Highlighted in Three Data Presentations at Keystone Symposia Conferences 5:01 p.m. March 4, 2014 - Marketwire
Peregrine Pharmaceuticals to Report Third Quarter Fiscal Year 2014 Financial Results Before Market Open on March 7, 2014 5:01 p.m. Feb. 27, 2014 - Marketwire
Peregrine Pharmaceuticals Announces Partial Exercise of Overallotment Option in Connection With Preferred Stock Offering 1:20 p.m. Feb. 27, 2014 - Marketwire
Hercules Offshore Losses Decrease from $121 million to $27 million 10:17 a.m. Feb. 24, 2014 - ACCESSWIRE
(0)
(0)